{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T19:28:22Z","timestamp":1793820502869,"version":"4.6.1"},"reference-count":109,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journals.elsevierhealth.com","europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.eururo.2014.07.010","type":"journal-article","created":{"date-parts":[[2014,8,2]],"date-time":"2014-08-02T15:17:59Z","timestamp":1406992679000},"page":"825-836","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":744,"title":["Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them"],"prefix":"10.1016","volume":"67","author":[{"given":"Paul L.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shabbir M.H.","family":"Alibhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shehzad","family":"Basaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony V.","family":"D\u2019Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip W.","family":"Kantoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy L.","family":"Keating","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"Penson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek J.","family":"Rosario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Tombal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2014.07.010_bib0005","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1001\/jama.299.3.289","article-title":"Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial","volume":"299","author":"D\u2019Amico","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2014.07.010_bib0010","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1012348","article-title":"Radiotherapy and short-term androgen deprivation for localized prostate cancer","volume":"365","author":"Jones","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2014.07.010_bib0015","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1470-2045(11)70063-8","article-title":"Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial","volume":"12","author":"Denham","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2014.07.010_bib0020","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1056\/NEJM199707313370502","article-title":"Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin","volume":"337","author":"Bolla","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2014.07.010_bib0025","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1200\/JCO.2005.08.141","article-title":"Androgen suppression plus radiation versus radiation alone for patients with stage D1\/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31","volume":"23","author":"Lawton","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.07.010_bib0030","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJM199912093412401","article-title":"Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer","volume":"341","author":"Messing","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2014.07.010_bib0035","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0022-5347(01)61639-2","article-title":"Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma","volume":"161","author":"Maillefert","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2014.07.010_bib0040","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0022-5347(05)64985-3","article-title":"Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy","volume":"167","author":"Berruti","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2014.07.010_bib0045","first-page":"288","article-title":"Decreased bone density in elderly men treated with the gonadotropin-releasing hormone agonist decapeptyl (D-Trp6-GnRH)","volume":"76","author":"Goldray","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eururo.2014.07.010_bib0050","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0022-5347(05)68000-7","article-title":"Progressive osteoporosis during androgen deprivation therapy for prostate cancer","volume":"163","author":"Daniell","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2014.07.010_bib0055","doi-asserted-by":"crossref","first-page":"7897","DOI":"10.1200\/JCO.2004.00.6908","article-title":"Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer","volume":"23","author":"Smith","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.07.010_bib0060","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer","volume":"352","author":"Shahinian","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2014.07.010_bib0065","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1634\/theoncologist.2012-0051","article-title":"Calcium and vitamin D supplementation during androgen deprivation therapy for prostate cancer: a critical review","volume":"17","author":"Datta","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.eururo.2014.07.010_bib0070","unstructured":"Clinician's guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation Web site. http:\/\/www.nof.org\/files\/nof\/public\/content\/file\/344\/upload\/159.pdf."},{"key":"10.1016\/j.eururo.2014.07.010_bib0075","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1056\/NEJMoa010845","article-title":"Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer","volume":"345","author":"Smith","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2014.07.010_bib0080","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.ijrobp.2012.11.007","article-title":"Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy","volume":"85","author":"Choo","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2014.07.010_bib0085","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1097\/01.ju.0000063820.94994.95","article-title":"Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer","volume":"169","author":"Smith","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2014.07.010_bib0090","doi-asserted-by":"crossref","first-page":"416","DOI":"10.7326\/0003-4819-146-6-200703200-00006","article-title":"Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial","volume":"146","author":"Greenspan","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eururo.2014.07.010_bib0095","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.eururo.2012.09.007","volume":"63","author":"Klotz","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.07.010_bib0100","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/pcan.2011.4","article-title":"Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis","volume":"15","author":"Serpa Neto","year":"2012","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2014.07.010_bib0105","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2014.07.010_bib0110","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1210\/jc.2003-032058","article-title":"Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial","volume":"89","author":"Smith","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eururo.2014.07.010_bib0115","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.juro.2010.06.022","article-title":"Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer","volume":"184","author":"Smith","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2014.07.010_bib0120","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1200\/JCO.2004.01.174","article-title":"Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition","volume":"22","author":"Smith","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.07.010_bib0125","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1097\/01.ju.0000127738.94221.da","article-title":"Bicalutamide 150mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer","volume":"171","author":"Sieber","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2014.07.010_bib0130","doi-asserted-by":"crossref","first-page":"566","DOI":"10.7326\/0003-4819-132-7-200004040-00009","article-title":"Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis","volume":"132","author":"Seidenfeld","year":"2000","journal-title":"Ann Intern Med"},{"issue":"Suppl 3","key":"10.1016\/j.eururo.2014.07.010_bib0135","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2013.0215","article-title":"NCCN Task Force Report: Bone Health in Cancer Care","volume":"11","author":"Gralow","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.eururo.2014.07.010_bib0140","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.6004\/jnccn.2012.0114","article-title":"Prostate cancer, version 3.2012: featured updates to the NCCN guidelines","volume":"10","author":"Mohler","year":"2012","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.eururo.2014.07.010_bib0145","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1210\/jcem.87.2.8299","article-title":"Changes in body composition during androgen deprivation therapy for prostate cancer","volume":"87","author":"Smith","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eururo.2014.07.010_bib0150","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1210\/jc.2005-2507","article-title":"Insulin sensitivity during combined androgen blockade for prostate cancer","volume":"91","author":"Smith","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eururo.2014.07.010_bib0155","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/cncr.21642","article-title":"Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy","volume":"106","author":"Basaria","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2014.07.010_bib0160","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer","volume":"24","author":"Keating","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.07.010_bib0165","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/jnci\/djp404","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer","volume":"102","author":"Keating","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2014.07.010_bib0170","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/jnci\/djp404","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. [published correction appears in J Natl Cancer Inst 2012; 104: 1518-23]","volume":"102","author":"Keating","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2014.07.010_bib0175","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2008.20.0923","article-title":"Impact of androgen deprivation therapy on cardiovascular disease and diabetes","volume":"27","author":"Alibhai","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.07.010_bib0180","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel, III)","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2014.07.010_bib0185","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1210\/jcem.86.9.7851","article-title":"The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer","volume":"86","author":"Smith","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eururo.2014.07.010_bib0190","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1200\/JCO.2006.05.9741","article-title":"Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy","volume":"24","author":"Braga-Basaria","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.07.010_bib0195","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1111\/j.1464-410X.2011.10555.x","article-title":"A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy","volume":"109","author":"Nobes","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2014.07.010_bib0200","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1200\/JCO.2003.09.534","article-title":"Resistance exercise in men receiving androgen deprivation therapy for prostate cancer","volume":"21","author":"Segal","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.07.010_bib0205","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1123\/japa.21.4.455","article-title":"A randomized trial of aerobic versus resistance exercise in prostate cancer survivors","volume":"21","author":"Santa Mina","year":"2013","journal-title":"J Aging Phys Act"},{"key":"10.1016\/j.eururo.2014.07.010_bib0210","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/pon.1023","article-title":"Active for Life After Cancer: a randomized trial examining a lifestyle physical activity program for prostate cancer patients","volume":"15","author":"Carmack Taylor","year":"2006","journal-title":"Psychooncology"},{"key":"10.1016\/j.eururo.2014.07.010_bib0215","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1186\/1471-2407-9-419","article-title":"A randomized controlled trial of an exercise intervention targeting cardiovascular and metabolic risk factors for prostate cancer patients from the RADAR trial","volume":"9","author":"Galvao","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1016\/j.eururo.2014.07.010_bib0220","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1186\/1471-2407-12-432","article-title":"Can exercise ameliorate treatment toxicity during the initial phase of testosterone deprivation in prostate cancer patients? Is this more effective than delayed rehabilitation?","volume":"12","author":"Newton","year":"2012","journal-title":"BMC Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.eururo.2014.07.010_bib0225","first-page":"S11","article-title":"American Diabetes, Association. Standards of medical care in, diabetes\u20142013","volume":"36","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eururo.2014.07.010_bib0230","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.eururo.2013.02.023","article-title":"Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer","volume":"65","author":"Keating","year":"2014","journal-title":"Eur Urol"},{"issue":"Suppl 2","key":"10.1016\/j.eururo.2014.07.010_bib0235","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.eururo.2014.07.010_bib0240","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1093\/jnci\/djm168","article-title":"Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality","volume":"99","author":"Tsai","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2014.07.010_bib0245","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1200\/JCO.2006.09.3369","article-title":"Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions","volume":"25","author":"D\u2019Amico","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.07.010_bib0250","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1161\/CIRCULATIONAHA.109.192695","article-title":"Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology","volume":"121","author":"Levine","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.eururo.2014.07.010_bib0255","unstructured":"FDA drug safety communication: Update to ongoing safety review of GnRH agonists and notification to manufacturers of GnRH agonists to add new safety information to labeling regarding increased risk of diabetes and certain cardiovascular diseases. US Food and Drug Administration Web site. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm229986.htm. Accessed August 17, 2011."},{"key":"10.1016\/j.eururo.2014.07.010_bib0260","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.eururo.2011.08.041","article-title":"Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer","volume":"60","author":"Azoulay","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.07.010_bib0265","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.eururo.2012.01.045","article-title":"Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism","volume":"61","author":"Hu","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.07.010_bib0270","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1200\/JCO.2010.29.1567","article-title":"Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden","volume":"28","author":"Van Hemelrijck","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.07.010_bib0275","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.eururo.2013.02.002","article-title":"Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study","volume":"65","author":"Jespersen","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.07.010_bib0280","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1200\/JCO.2011.35.1494","article-title":"Androgen deprivation therapy and cardiovascular risk","volume":"29","author":"Punnen","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.07.010_bib0285","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JCO.2007.12.3752","article-title":"Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31","volume":"27","author":"Efstathiou","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.07.010_bib0290","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1200\/JCO.2007.13.9881","article-title":"Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610","volume":"26","author":"Roach","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.07.010_bib0295","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1159\/000334999","article-title":"Androgen deprivation therapy for prostate cancer does not increase cardiovascular mortality in the long term","volume":"82","author":"Wilcox","year":"2012","journal-title":"Oncology"},{"key":"10.1016\/j.eururo.2014.07.010_bib0300","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.eururo.2008.01.021","article-title":"Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02","volume":"54","author":"Efstathiou","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.07.010_bib0305","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1001\/jama.2011.1745","article-title":"Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials","volume":"306","author":"Nguyen","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2014.07.010_bib0310","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/bjc.2012.523","article-title":"Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness?","volume":"108","author":"Bourke","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2014.07.010_bib0315","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1001\/jama.291.20.2441","article-title":"Prognostic importance of comorbidity in a hospital-based cancer registry","volume":"291","author":"Piccirillo","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2014.07.010_bib0320","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1001\/jama.2009.1137","article-title":"Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction","volume":"302","author":"Nanda","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2014.07.010_bib0325","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.ijrobp.2011.04.067","article-title":"Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction","volume":"82","author":"Nguyen","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2014.07.010_bib0330","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.eururo.2012.04.035","article-title":"Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer?","volume":"64","author":"Keating","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.07.010_bib0335","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1016\/j.juro.2010.08.012","article-title":"Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer","volume":"184","author":"Smith","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2014.07.010_bib0340","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.juro.2011.07.035","article-title":"Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix","volume":"186","author":"Smith","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2014.07.010_bib0345","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.eururo.2013.10.032","article-title":"Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist","volume":"65","author":"Albertsen","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.07.010_bib0350","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1046\/j.1365-2265.2002.01551.x","article-title":"Long-term effects of androgen deprivation therapy in prostate cancer patients","volume":"56","author":"Basaria","year":"2002","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.eururo.2014.07.010_bib0355","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1200\/JCO.2012.41.8509","article-title":"Sexuality and intimacy after definitive treatment and subsequent androgen deprivation therapy for prostate cancer","volume":"30","author":"Higano","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.07.010_bib0360","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1002\/cncr.11233","article-title":"Patient satisfaction with treatment decisions for clinically localized prostate carcinoma. Results from the Prostate Cancer Outcomes Study","volume":"97","author":"Hoffman","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2014.07.010_bib0365","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1201546","article-title":"Intermittent androgen suppression for rising PSA level after radiotherapy","volume":"367","author":"Crook","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2014.07.010_bib0370","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1056\/NEJMoa1212299","article-title":"Intermittent versus continuous androgen deprivation in prostate cancer","volume":"368","author":"Hussain","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2014.07.010_bib0375","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1056\/NEJMoa0810095","article-title":"Duration of androgen suppression in the treatment of prostate cancer","volume":"360","author":"Bolla","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2014.07.010_bib0380","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/S1470-2045(12)70423-0","article-title":"Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial","volume":"13","author":"Denham","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2014.07.010_bib0385","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/pcan.2012.52","article-title":"Exercise maintains sexual activity in men undergoing androgen suppression for prostate cancer: a randomized controlled trial","volume":"16","author":"Cormie","year":"2013","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2014.07.010_bib0390","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ijrobp.2004.03.022","article-title":"Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia","volume":"60","author":"Tyrrell","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2014.07.010_bib0395","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/S1470-2045(05)70464-2","article-title":"Management of gynaecomastia in patients with prostate cancer: a systematic review","volume":"6","author":"Di Lorenzo","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2014.07.010_bib0400","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0090-4295(02)02107-6","article-title":"Does prophylactic breast irradiation prevent antiandrogen-induced gynecomastia? Evaluation of 253 patients in the randomized Scandinavian trial SPCG-7\/SFUO-3","volume":"61","author":"Widmark","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2014.07.010_bib0405","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1200\/JCO.2005.12.013","article-title":"Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer","volume":"23","author":"Boccardo","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.07.010_bib0410","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1097\/01.ju.0000181824.28382.5c","article-title":"Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy","volume":"174","author":"Di Lorenzo","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2014.07.010_bib0415","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S1470-2045(05)70103-0","article-title":"Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial","volume":"6","author":"Perdona","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2014.07.010_bib0420","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S0022-5347(17)43497-5","article-title":"Effect of treatment with chronic gonadotropin releasing hormone agonist on human testis","volume":"138","author":"Hadziselimovic","year":"1987","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2014.07.010_bib0425","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.juro.2006.08.113","article-title":"Penile length changes in men treated with androgen suppression plus radiation therapy for local or locally advanced prostate cancer","volume":"177","author":"Haliloglu","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2014.07.010_bib0430","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.urology.2012.08.068","article-title":"Reduced penile size and treatment regret in men with recurrent prostate cancer after surgery, radiotherapy plus androgen deprivation, or radiotherapy alone","volume":"81","author":"Parekh","year":"2013","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2014.07.010_bib0435","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00520-011-1271-0","article-title":"Clinical exercise interventions in prostate cancer patients\u2014a systematic review of randomized controlled trials","volume":"20","author":"Baumann","year":"2012","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.eururo.2014.07.010_bib0440","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1200\/JCO.2009.23.2488","article-title":"Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial","volume":"28","author":"Galv\u00e3o","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.07.010_bib0445","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.eururo.2013.09.040","article-title":"Lifestyle changes for improving disease-specific quality of life in sedentary men on long-term androgen-deprivation therapy for advanced prostate cancer: a randomised controlled trial","volume":"65","author":"Bourke","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.07.010_bib0450","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00520-009-0694-3","article-title":"Physical activity for men receiving androgen deprivation therapy for prostate cancer: benefits from a 16-week intervention","volume":"18","author":"Culos-Reed","year":"2010","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.eururo.2014.07.010_bib0455","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1745-6215-11-86","article-title":"A randomised controlled trial to evaluate the efficacy of a 6 month dietary and physical activity intervention for prostate cancer patients receiving androgen deprivation therapy","volume":"11","author":"Haseen","year":"2010","journal-title":"Trials"},{"key":"10.1016\/j.eururo.2014.07.010_bib0460","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/annonc\/mdn644","article-title":"A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB)","volume":"20","author":"Loprinzi","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2014.07.010_bib0465","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1470-2045(09)70338-9","article-title":"Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial","volume":"11","author":"Irani","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2014.07.010_bib0470","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1016\/j.juro.2009.07.030","article-title":"Lack of an effect of high dose isoflavones in men with prostate cancer undergoing androgen deprivation therapy","volume":"182","author":"Sharma","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2014.07.010_bib0475","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1200\/JCO.2012.48.1432","article-title":"Randomized trial to assess the impact of venlafaxine and soy protein on hot flashes and quality of life in men with prostate cancer","volume":"31","author":"Vitolins","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.07.010_bib0480","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00520-009-0589-3","article-title":"Acupuncture for treating hot flushes in men with prostate cancer: a systematic review","volume":"17","author":"Lee","year":"2009","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.eururo.2014.07.010_bib0485","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1464-410X.2008.07884.x","article-title":"Auricular acupuncture: a novel treatment for vasomotor symptoms associated with luteinizing-hormone releasing hormone agonist treatment for prostate cancer","volume":"103","author":"Harding","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2014.07.010_bib0490","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.ijrobp.2010.01.025","article-title":"Acupuncture for the alleviation of hot flashes in men treated with androgen ablation therapy","volume":"79","author":"Ashamalla","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2014.07.010_bib0495","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1210\/jc.2002-020419","article-title":"Longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderly men","volume":"87","author":"Moffat","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eururo.2014.07.010_bib0500","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1046\/j.1464-410X.2002.02917.x","article-title":"Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial","volume":"90","author":"Green","year":"2002","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2014.07.010_bib0505","doi-asserted-by":"crossref","first-page":"5030","DOI":"10.1200\/JCO.2010.30.8742","article-title":"Impact of androgen-deprivation therapy on cognitive function in men with nonmetastatic prostate cancer","volume":"28","author":"Alibhai","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.07.010_bib0510","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1186\/1471-2407-12-324","article-title":"Efficacy of walking exercise in promoting cognitive-psychosocial functions in men with prostate cancer receiving androgen deprivation therapy","volume":"12","author":"Lee","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.eururo.2014.07.010_bib0515","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/aja.2011.102","article-title":"Hematological changes during androgen deprivation therapy","volume":"14","author":"Grossmann","year":"2012","journal-title":"Asian J Androl"},{"key":"10.1016\/j.eururo.2014.07.010_bib0520","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/(SICI)1096-8652(199811)59:3<230::AID-AJH8>3.0.CO;2-2","article-title":"Anemia after orchiectomy","volume":"59","author":"Fonseca","year":"1998","journal-title":"Am J Hematol"},{"key":"10.1016\/j.eururo.2014.07.010_bib0525","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/cncr.10673","article-title":"Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer","volume":"95","author":"D\u2019Amico","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2014.07.010_bib0530","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1007\/s00520-010-1023-6","article-title":"Predictors of hemoglobin decline in non-metastatic prostate cancer patients on androgen deprivation therapy: a matched cohort study","volume":"19","author":"Timilshina","year":"2011","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.eururo.2014.07.010_bib0535","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/cncr.22029","article-title":"The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer: a multivariate analysis of Southwest Oncology Group Study 8894","volume":"107","author":"Beer","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2014.07.010_bib0540","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1464-410X.2005.06051.x","article-title":"Bicalutamide 150mg plus standard care vs standard care alone for early prostate cancer","volume":"97","author":"McLeod","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2014.07.010_bib0545","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ctrv.2008.08.002","article-title":"A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma","volume":"35","author":"Shelley","year":"2009","journal-title":"Cancer Treat Rev"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283814006502?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283814006502?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T10:03:27Z","timestamp":1565690607000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283814006502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":109,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S0302283814006502"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2014.07.010","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718521683.793556666","asserted-by":"object"}]},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2014.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}